Innovation with Intent
At Terumo, we innovate with intent to achieve the best possible outcomes. Our uniquely engineered radial and femoral sheaths and closure devices push the boundaries in treatment regardless of the access site.
The Terumo radial and femoral access and closure solutions provide:
- Lower risk of complications1,2,3
- Improved patient comfort and satisfaction4,5
- Reduced length of stay6
- Opportunity for same day discharge6
Our radial and femoral access and closure portfolio for vascular access site management include:
1. Complications with Angio-Seal vascular closure devices compared with manual compression after diagnostic cardiac catheterization and percutaneous coronary intervention, Gregory D, Midodzi W, Pearce N. J Interven Cardiol. 2013;26:630-638.
2. Registry based prospective, active surveillance of medical-device safety, Resnic FS, Majithia A, Marinec-Dabic D, Robbins S, Ssemaganda H, Hewitt K, Pnikaris A, Loyo-Berrios N, Moussa I, Drozda J, Normand SL, Matheny ME. N Engl J Med. 2017 Feb 9;376(6):526-535.
3. Usefulness of a Gentle and Short Hemostasis Using the Transradial Band Device after Transradial Access for Percutaneous Coronary Angiography and Interventions to Reduce the Radial Artery Occlusion Rate (from the Prospective and Randomized CRASOC I, II, and III Studies), Vincent Dangoisse, MDa,*, Antoine Guédès, MDa, Patrick Chenu, MDb, Claude Hanet, MDa, Clara Albert, LScIa, Valérie Robin, BSN, MPHa, Laurence Tavier, BSN, MPHa, Christine Dury, LScIa, Olivier Piraux, LScIa, Juliette Domange, RNa, Karine Jourdan, RNa, Benoit Bihin, MScc, and Erwin Schroeder, MDa. The American Journal of Cardiology. August 1, 2017; 374-379.
4. Effectiveness and safety of transradial artery access for cardiac catheterization, Jeffrey M. Schussler, MD. Baylor University Medical Center Proceedings. July 1, 2017; 205-209.
5. Femoral arterial puncture management after percutaneous coronary procedures: A comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices, Duffin DC, Muhlestein JB, Allisson SB, Horne BD, Fowles RE, Sorenson SG, Lappe DL. Journal of Invasive Cardiology. 2001;13(5), 354-362.
6. The 6Fr Angio-Seal arterial closure device: Results from a multimember prospective registry, Kapadia SR, Raymond R, Knopf W, Jenkins S, Chapekis A, Ansel G, Rothbaum D, Kussmaul W, Teirstein P, Reisman M, Casale P, Oster L, Simfendorfer C. Am J Cardiol. 2001; 87:789-791.
The Angio-Seal Vascular Closure Device product family, including the STS Plus, VIP and Evolution platforms, is indicated for use in closing and reducing time to hemostasis of the femoral arterial puncture site in patients who have undergone diagnostic angiography procedures or interventional procedures using an 8 French or smaller procedural sheath for the 8 F Angio-Seal device and a 6 French or smaller procedural sheath for the 6 F Angio-Seal device. The Angio-Seal STS Plus, VIP and Evolution platform devices are also indicated for use to allow patients who have undergone diagnostic angiography to safely ambulate as soon as possible after sheath removal and device placement, as well as to allow patients who have undergone an interventional procedure to safely ambulate after sheath removal and device placement.
Important Safety Information:
Possible adverse events for vascular closure devices include, but are not limited to: bleeding or hematoma, AV fistula or pseudoaneurysm, infection, allergic reaction, foreign body reaction, inflammation or edema. This device should only be used by a licensed physician (or other health care professional authorized by or under the direction of such physician) possessing adequate instruction in the use of the device, e.g., participation in an Angio-Seal physician instruction program or equivalent.
RX ONLY. Refer to the product labels and package insert for complete warnings, precautions, potential complications, and instructions for use.